Core Viewpoint - The 2026 Chinese equity market is expected to enter a "long cycle, structural bull market," while the bond market will shift to a phase of volatility, and a super cycle for commodities may gradually begin, with global asset allocation focusing more on China [1][7]. Group 1: Chinese Equity Market - In the first 11 months of 2025, global major assets showed a comprehensive increase, with the South Korean Composite Index and COMEX gold rising over 60%, while the CSI 300 and Hang Seng Index increased over 25% [3][9]. - Foreign capital inflow into the Chinese stock market reached $50.6 billion in the first 10 months of 2025, significantly surpassing the total of $11.4 billion for the entire year of 2024 [3][9]. - The allocation ratio of global active mutual funds to Chinese stocks is currently at 6.4%, which is below the historical average of 9%, indicating significant room for growth [3][9]. - The equity allocation ratio of domestic wealth management products is only 2.1%, and if it rises to the average of 5.44% from 2017 to 2024, it could bring an additional 1.15 trillion yuan [3][9]. - The investment themes for 2024 Q3 to 2025 Q3 will focus on "innovative drugs + technology growth" (including innovative drugs, computers, and semiconductors), with energy storage and lithium batteries taking over in Q4 2025, and chemicals and consumer sectors entering a recovery cycle in 2026 [3][9]. Group 2: Bond Market - The rapid decline in bond market interest rates has ended, with the policy interest rate reduction space narrowing to 10-20 basis points, and the 10-year government bond yield expected to fluctuate between 1.5% and 1.9%, while the 30-year yield is projected to be between 1.8% and 2.3% [4][10]. - The bond market's single-sided bull market has concluded, and future trends are expected to be dominated by volatility [4][10]. Group 3: Commodity Market - Current commodity prices are at multi-decade lows relative to U.S. stocks, with the commodity equity ratio approaching historical lows, and gold has already begun to rise, along with noticeable increases in copper and aluminum prices [4][10]. - A new super cycle for commodities is anticipated, driven by global interest rate cuts, economic recovery, and factors such as the U.S. being the only source of growth in global oil production and OPEC+ reaching production limits [4][10].

Core Viewpoint - The A+H pharmaceutical sector continues to adjust, with significant fluctuations in the market, particularly in innovative drugs, indicating potential investment opportunities as bottom-fishing capital emerges [1][5][16]. Group 1: Market Performance - The largest medical ETF in the market (512170) and the only drug ETF (562050) fell by 0.58% and 0.19% respectively, while the Hong Kong innovative drug ETF (520880) dropped by 1.43% [1][5]. - A-share medical leaders mostly declined, with WuXi AppTec down 2.01%, and both Aier Eye Hospital and Tigermed down over 1%, while some stocks like Yingke Medical and New Industry saw gains [1][12]. - The medical ETF (512170) hit a four-month low during intraday trading, closing below all moving averages, but saw over 1.14 billion yuan in net subscriptions as investors sought to buy the dip [1][16]. Group 2: Sector Analysis - The pharmaceutical sector in A-shares showed relative resilience, with the drug ETF (562050) outperforming the market, primarily due to gains from traditional Chinese medicine leaders like Pian Zai Huang and Yunnan Baiyao [3][12]. - The innovative drug sector displayed divergence, with Yifan Pharmaceutical surging by 6.11%, while major stocks like BeiGene fell by 1.59% [3][12]. - The drug ETF (562050) has about 25% weight in traditional Chinese medicine, which helps mitigate the high volatility of innovative drugs, thus reducing the overall volatility and drawdown of the pharmaceutical index [3][12]. Group 3: Future Outlook - The innovative drug sector is expected to be a major upward trend heading into 2026, as the industry continues to experience strong demand and unmet needs, with increased R&D investments from pharmaceutical companies [7][16]. - Analysts suggest that the current adjustment phase may present a favorable long-term investment opportunity in pharmaceutical assets, particularly as the sector shows signs of recovery [16]. - The Hong Kong innovative drug ETF (520880) is recommended for balanced internal allocation strategies, with a focus on improving fundamentals in the innovative drug supply chain [7][16].

Core Viewpoint - APL-1401, an innovative oral drug developed by the company for the treatment of moderate to severe active ulcerative colitis, has had its phase Ib clinical trial results selected for presentation at the 19th European Colorectal Congress (ECC) [1] Group 1: Clinical Trial Results - The phase Ib clinical trial results of APL-1401 were presented in poster format at the ECC [1] - APL-1401 is designed to treat autoimmune diseases through a novel mechanism of action [1] Group 2: Drug Mechanism - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor [1] - By inhibiting DBH, APL-1401 blocks the only catalytic enzyme for the synthesis of norepinephrine (NE) from dopamine (DA), leading to increased DA and decreased NE, which helps restore intestinal immune homeostasis [1]

Group 1 - The Hong Kong stock market rebounded last week, with the Hang Seng Index rising by 2.53% or 638 points, closing at 25,858 points, despite a decrease in trading volume [1] - The overall trading volume for the week was approximately 1.09 trillion HKD, and the market remained flat for November [1] - The market is experiencing volatility due to differing views on AI narratives and a tendency for profit-taking as year-end approaches, although long-term external liquidity conditions are expected to improve [1] Group 2 - Technology stocks are gaining attention due to significant investments in AI infrastructure, with the launch of Alibaba's Quark AI glasses and Ant Group's Lingguang App generating positive market reactions [2] - The innovative drug industry is seeing opportunities as major pharmaceutical companies engage in large-scale mergers to address patent cliffs, with Eli Lilly becoming the first pharmaceutical company to surpass a market value of 1 trillion USD [2] - China is positioned as a key player in the global biopharmaceutical market, with potential growth for certain Hong Kong-listed innovative drug companies as the industry evolves [2]

今天又超过4000家公司下跌，大跌的公司其实并不多，但最近的盘面，就是持续的阴跌，其难受程度，远不如4月给人一个痛快。 从10月至今，市场超过3000家公司是大跌的，涨10个点以上的公司1100家（10个点以内可以理解为震荡行情）。如果我们按10月至 今的区间最高价算到昨天收盘价，回撤10个点以上的公司有3300家，回撤超过15个点的有2049家，回撤超过20个点的有1024只。 所以，这段时间，虽然上证指数回撤并没有多少，但应该不少人的回撤是很大的。 如果配了港股，那会更加悲剧，因为就恒生科技指数来说，最高下来回撤了近20%，个股回撤2、30个点的一抓一大把，说港股一脚 已经踏入熊市，都不算过分的。 这就引出了一个灵魂问题：牛市到底还在不在？ 我们从这波回撤的原因，当前的市场环境来讨论这个问题。 01 高位很高，低位不济 10月至今这波回撤，要说原因的话，我觉得就是8个字，高位很高，低位不济。 10月之前，创新药猛猛涨了一波，半导体猛猛涨了一波，AI猛猛涨了一波。这些方向的估值都非常高，如果没有更新的进展来打鸡 血，震荡消化估值是不可避免的。像光模块方向因为实不实又被美帝那边的进展打下鸡血，还有铜铝也加上了 ...

Core Viewpoint - The current market environment is characterized by a significant number of companies experiencing declines, with over 3,000 companies seeing substantial drops since October, despite the Shanghai Composite Index showing limited retreat [4][5]. Market Performance - Since October, more than 3,000 companies have faced significant declines, with 1,100 companies rising by over 10%. A total of 3,300 companies have retreated by more than 10%, 2,049 by over 15%, and 1,024 by over 20% [4]. - The Hang Seng Technology Index has seen a nearly 20% drop, with individual stocks experiencing declines of 20-30% [5]. Market Sentiment - The question of whether a bull market still exists is raised, with the current sentiment suggesting a struggle due to high valuations and weak fundamentals [6][7]. Reasons for Market Retreat - The recent market retreat is attributed to high valuations in sectors like innovative pharmaceuticals, semiconductors, and AI, which have not seen new developments to justify their prices [9]. - The consumer sector, particularly in areas like liquor, has also shown weakness, with companies like Moutai hitting new lows [11]. Economic Environment - The macroeconomic environment remains weak, with indicators such as PMI orders declining and consumer spending showing no signs of recovery [14]. - Predictions indicate that housing prices may continue to decline, impacting household wealth and consumer confidence [15][17]. Future Outlook - The government is expected to increase liquidity support, especially with the upcoming Federal Reserve meeting and domestic economic conferences [18][19]. - The technology sector is anticipated to remain a focal point, with potential opportunities for bottom-fishing in specific segments [20]. - The market may experience a difficult period for another half month, but the bull market is still considered to be intact, pending macroeconomic support [23].

Core Insights - The report by Morgan Asset Management highlights a complex yet opportunity-rich environment as investors approach 2026, driven by AI technology and influenced by global trade and geopolitical dynamics [1] Economic Outlook - The global economy is expected to exhibit a "strong first, weak later" growth pattern, with different economies showcasing their unique narratives [1] - China is entering the first year of its "15th Five-Year Plan," focusing on "de-involution" and industrial upgrades, which are expected to foster new growth momentum [1] - The U.S. may experience moderate growth as fiscal stimulus effects wane, with the pace of monetary policy shifts being a critical variable [1] - Europe faces a delicate balance between fiscal expansion and debt discipline [1] - Emerging markets in Asia are poised to benefit from deep integration into the global AI supply chain, presenting unique development opportunities [1] Investment Strategy - Future investment returns will increasingly depend on a profound understanding of global growth disparities and policy rhythms, alongside flexible cross-market allocation capabilities [2] - Morgan Asset Management emphasizes the importance of global allocation capabilities, leveraging its research network and local insights to identify high-quality companies with long-term growth potential [2] - Key sectors for investment include technology, industrials, communication services, and materials, with a focus on companies that can translate technology into business value, such as AI firms and traditional industry leaders undergoing digital transformation [2] AI and Market Dynamics - The rapid development of AI applications is significantly increasing spending on software, hardware, and cloud resources, creating opportunities for tech providers while raising concerns about infrastructure bottlenecks and rising costs [3] - AI is expected to disrupt traditional business models, with the rise of physical AI applications like autonomous vehicles and robots further expanding its impact [3] - Investors are advised to discern which AI models and large-scale cloud service providers are likely to succeed [3]

行业配置方面，该机构预计，在日历效应及美联储降息周期叠加影响下，12月科技成长、部分周期和消 费可能相对占优，建议继续均衡配置：一是政策和产业趋势向上的电子（半导体、AI硬件）、通信 （AI硬件）、传媒（AI应用、游戏）、计算机（AI应用）、电新（储能、锂电）、创新药、机械设备 （机器人）等行业；二是可能补涨和基本面可能边际改善的消费（食品、商贸零售等）、大金融、军工 （商业航天）等行业。 华金证券发布研报称，12月A股可能震荡偏强，上行趋势不变。理由在于，12月政策和外部事件可能偏 积极，流动性可能进一步宽松，且经济和企业盈利可能延续弱修复趋势。 上证报中国证券网讯（记者 严晓菲）华金证券发布研报称，12月A股可能震荡偏强，上行趋势不变。理 由在于，12月政策和外部事件可能偏积极，流动性可能进一步宽松，且经济和企业盈利可能延续弱修复 趋势。 ...

今天分享的是：自免行业报告(二)：PROTAC实现"0-1"突破，看好自免口服破局潜力 报告共计：43页 PROTAC技术发展与自免领域应用潜力总结 本报告聚焦PROTAC（蛋白降解靶向嵌合体）技术，深入分析其机制优势、行业现状及在自身免疫性疾病（自免）领域的应用潜力。 PROTAC通过双功能小分子将目标蛋白与细胞内E3泛素连接酶拉近，借助泛素蛋白酶体系统降解目标蛋白，具备独特优势：可靶向传统小分子抑制剂难以作 用的"不可成药"蛋白，能克服靶点突变或表达上调导致的耐药性，且因催化特性具有高选择性和低剂量优势，除肿瘤外，在自免疾病等领域展现出广阔应用 前景。目前约80%的临床PROTAC针对癌症，技术整体处于早期阶段，分子结构设计仍有较大迭代空间。 与竞争激烈的肿瘤领域不同，自免口服药物市场尚处蓝海，尤其皮肤科药物市场潜力巨大。2023年银屑病整体市场规模达270亿美金，口服药物仅占9%，据 预测，2034年左右其市占率有望提升至33%。自免领域仍有大量未被满足的需求，约50%-70%的银屑病/IBD患者未接受先进疗法，且75%的注射性药物使用 者愿意切换至口服药物，而PROTAC兼具类生物制剂的疗效与安全性， ...

Group 1 - The Hong Kong innovative drug sector continues to adjust, with leading stocks collectively declining and the Hong Kong Stock Connect innovative drug ETF (520880) falling over 1% for four consecutive days, despite strong buying interest in the market [1] - The launch of the China Drug Price Registration System on December 2 is expected to benefit the global market development of innovative drugs [1] - Analysts believe that the trend of the innovative drug industry will remain unchanged by 2026, indicating potential for rebound after the current adjustments [1] Group 2 - Investment in innovative drugs can be primarily directed towards the Hong Kong Stock Connect innovative drug ETF (520880) and its off-market linked fund (025221), which have three major advantages in their underlying index [1] - As of November 30, the ETF has a scale of 2.142 billion yuan, with an average daily trading volume of 458 million yuan since its listing [1]